Market Overview

Orexigen, Takeda Report Multiple Contrave Data Presentations at ObesityWeek

Related OREX
Takeda And Orexigen Announce FDA Approval of Contrave Extended-release Tablets For Chronic Weight Management
Benzinga's Top #PreMarket Losers

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc. (Takeda), today announced multiple Contrave® (naltrexone sustained release (SR)/bupropion SR) abstracts accepted for poster presentations and an oral presentation at the upcoming ObesityWeek meeting. This meeting will be held November 11-16, 2013 in Atlanta at the Georgia World Congress Center.

Details on the presentation times are as follows:

Oral Presentation: Thursday, November 14, 2013 - Abstract T-36-OR, Presentation time 3:00-4:30 EST, Georgia World Congress Center Presenter: Kevin D. Hall, Ph.D.; National Institutes of Health, NIDDK, Bethesda, MD, USA. Title: Dynamical Systems Modeling of Caloric Intake and Body Composition with Combination Naltrexone/Bupropion Therapy

Poster Presentation: Friday, November 15, 2013 - Abstract T-740-P, Presentation time 12:00-1:30PM EST, Georgia World Congress Center, Exhibit Hall A Presenter: Raymond A Plodkowski, MD; Scripps Clinic, La Jolla, CA, USA. Title: Early achievement of significant weight loss with naltrexone/bupropion is associated with additional weight loss at one year – an integrated analysis of four Phase 3 trials

Poster Presentation: Friday, November 15, 2013 - Abstract T-741-P, Presentation time 12:00-1:30PM EST, Georgia World Congress Center, Exhibit Hall A Presenter: Susan McElroy, MD; Research Institute, Lindner Center of HOPE, Mason, OH, USA. Title: Naltrexone/bupropion is associated with early and longer-term improvement in binge eating disorder that is related to improvement in depression

Posted-In: News

 

Related Articles (OREX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional